Structure Therapeutics (GPCR) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 35.2% versus a loss of 6.1%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | ZBIO |
|---|---|---|
| Share price | $25.67 | $26.24 |
| Market cap | $1.83B | $1.71B |
| 1-day change | -3.79% | -6.88% |
| YTD return | -61.64% | -22.39% |
| 1-year return | -6.12% | +35.16% |
| EPS (TTM) | $-3.03 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $94.90 | $44.60 |
| 52-week low | $25.09 | $13.50 |
| Distance from 52-week high | -72.95% | -41.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +312.08% | +82.47% |
| Average volume | 957.51K | 735.12K |
| Shares outstanding | 71.31M | 65.18M |
| Employees | 281 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed GPCR by 41.3 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
GPCR vs ZBIO FAQ
Which is bigger, Structure Therapeutics or Zenas BioPharma?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.71B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, GPCR or ZBIO?
ZBIO returned +35.16% over the past 12 months, compared with -6.12% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.